TaxTMI Login
Just a moment...
Press 'Enter' to add multiple search terms. Rules for Better Search
When case Id is present, search is done only for this
of 
of 
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
of of 
All Case Laws
of of All Case Laws
Note
Bookmark
Share
Don't have an account? Register Here
of <h1>Valuing physician samples for duty assessment under Central Excise Act: Tribunal clarifies</h1> <h3>Emil Pharmaceutical Industries P. Ltd. Versus Commr. of C. Ex., Thane-II</h3> Emil Pharmaceutical Industries P. Ltd. Versus Commr. of C. Ex., Thane-II - 2016 (334) E.L.T. 143 (Tri. - Mumbai) Issues involved: Valuation of physician samples for duty assessment u/s Section 4(1)(a) or Section 4A.Summary:The Appellate Tribunal CESTAT MUMBAI addressed a common issue involving five appeals related to the valuation of physician samples manufactured by the assessees and sold to brand name holders on a principal to principal basis. The period in question was from 1-4-2005 onwards, coinciding with the introduction of MRP based assessment for P & P Medicaments. The key question was whether these samples should be assessed to duty u/s Section 4(1)(a) or Section 4A.The Tribunal referred to a previous judgment in the case of M/s. Gelnova Laboratories (I) Pvt. Ltd. v. Commissioner of Central Excise, Belapur, where it was established that P.P. Medicaments are covered by Section 4A of the Central Excise Act, 1944. The Tribunal noted that the requirement of displaying the retail price is only for goods intended for sale, and since physician samples are not intended for sale, the need to indicate the retail sale price does not apply. Additionally, the Tribunal had consistently held the view that physician samples manufactured on a principal to principal basis should be assessed under Section 4(1)(a) of the Central Excise Act.Consequently, the appeals filed by the assessees were allowed, while those filed by the Revenue were dismissed.
TaxTMI 
TaxTMI 
